Gulf International Bank UK Ltd Has $10.16 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Gulf International Bank UK Ltd cut its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 113,767 shares of the medical equipment provider’s stock after selling 1,283 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Boston Scientific were worth $10,161,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Mn Services Vermogensbeheer B.V. raised its stake in Boston Scientific by 1.8% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 578,700 shares of the medical equipment provider’s stock worth $51,689,000 after acquiring an additional 10,200 shares in the last quarter. New York Life Investment Management LLC grew its holdings in shares of Boston Scientific by 1.2% during the fourth quarter. New York Life Investment Management LLC now owns 203,294 shares of the medical equipment provider’s stock worth $18,158,000 after purchasing an additional 2,488 shares during the last quarter. Cable Hill Partners LLC grew its holdings in shares of Boston Scientific by 5.5% during the fourth quarter. Cable Hill Partners LLC now owns 6,209 shares of the medical equipment provider’s stock worth $555,000 after purchasing an additional 323 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of Boston Scientific during the fourth quarter worth $94,000. Finally, Oregon Public Employees Retirement Fund grew its holdings in shares of Boston Scientific by 0.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 126,369 shares of the medical equipment provider’s stock worth $11,287,000 after purchasing an additional 360 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 144,305 shares of company stock valued at $14,954,985. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BSX shares. Citigroup lifted their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Stifel Nicolaus lifted their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Canaccord Genuity Group boosted their target price on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.39.

Boston Scientific Price Performance

Shares of BSX stock opened at $101.61 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $65.52 and a twelve month high of $107.17. The company has a market cap of $149.96 billion, a P/E ratio of 81.29, a P/E/G ratio of 2.79 and a beta of 0.80. The business has a fifty day simple moving average of $98.73 and a 200 day simple moving average of $89.95.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.